Eric J Burks, MD
Associate Professor, Pathology

Biography
Eric Burks, MD, studies screening-detected non-small cell lung cancer. Dr. Burks’ studies established the diagnostic criteria for an entity now known as pulmonary adenocarcinoma of low malignant potential (LMP) which has been internationally validated and shown to account for overdiagnosis in the National Lung Screening Trial (NLST). His work has further established angioinvasive lung adenocarcinoma as the most aggressive form of early-stage NSCLC. Patients with small (<2 cm) angioinvasive tumors benefit from surgical resection of the entire involved lung lobe whereas the remaining patients are adequately treated with parenchymal sparing approaches such as wedge resection. Dr. Burks is a provisional patent holder (BU-2023-026) for biomarkers associated with angioinvasive lung adenocarcinoma, a co-investigator on a U01, The Lung Pre-Cancer Atlas project, a site PI on two R01s and a co-PI on an American Society of Hematology grant. In addition, he directs hematopathology, the hematology laboratory, the immunohistochemistry and special procedures laboratory, including amyloid pathology, and the hemoglobin diagnostic reference laboratory at Boston Medical Center.
Other Positions
- Member, BU-BMC Cancer Center, Boston University
Education
- University of New Mexico School of Medicine, MD
- New Mexico State University, BS
Publications
- Published on 2/5/2025
Ning B, Chiu DJ, Pfefferkorn RM, Kefella Y, Kane E, Reyes-Ortiz V, Liu G, Zhang S, Liu H, Sultan L, Green E, Constant M, Spira AE, Campbell JD, Reid ME, Varelas X, Burks EJ, Lenburg ME, Mazzilli SA, Beane JE. Epithelial miR-149-5p up-regulation is associated with immune evasion in progressive bronchial premalignant lesions. bioRxiv. 2025 Feb 05. PMID: 39975222.
Read at: PubMed - Published on 1/30/2025
Subramaniam S, Napoleon MA, Lotfollahzadeh S, Kamal MH, Kurniawan H, Elsadawi M, Kenney D, Douam F, Bosmann M, Whelan S, Cabral H, Burks EJ, Zhao G, Kolachalama V, Ravid K, Chitalia V. Tryptophan metabolism reprogramming contributes to the prothrombotic milieu in mice and humans infected with SARS-CoV-2. bioRxiv. 2025 Jan 30. PMID: 39896681.
Read at: PubMed - Published on 9/4/2024
Zheng Y, Conrad RD, Green EJ, Burks EJ, Betke M, Beane JE, Kolachalama VB. Graph Attention-Based Fusion of Pathology Images and Gene Expression for Prediction of Cancer Survival. IEEE Trans Med Imaging. 2024 Sep; 43(9):3085-3097. PMID: 38587959.
Read at: PubMed - Published on 6/10/2024
Steiner D, Sultan L, Sullivan T, Liu H, Zhang S, LeClerc A, Alekseyev YO, Liu G, Mazzilli SA, Zhang J, Rieger-Christ K, Burks EJ, Beane J, Lenburg ME. Identification of a gene expression signature of vascular invasion and recurrence in stage I lung adenocarcinoma via bulk and spatial transcriptomics. bioRxiv. 2024 Jun 10. PMID: 38915565.
Read at: PubMed - Published on 5/22/2024
Steiner D, Park JA, Singh S, Potter A, Scalera J, Beane J, Suzuki K, Lenburg ME, Burks EJ. A computed tomography-based score indicative of lung cancer aggression (SILA) predicts lung adenocarcinomas with low malignant potential or vascular invasion. Cancer Biomark. 2024 May 22; CBM230456. PMID: 39058440.
Read at: PubMed - Published on 5/22/2024
Burks EJ, Sullivan TB, Rieger-Christ KM. Pulmonary adenocarcinoma of low malignant potential defines indolent NSCLC associated with overdiagnosis in the national lung screening trial. Cancer Biomark. 2024 May 22. PMID: 39058439.
Read at: PubMed - Published on 4/6/2024
Gindra RH, Zheng Y, Green EJ, Reid ME, Mazzilli SA, Merrick DT, Burks EJ, Kolachalama VB, Beane JE. Graph Perceiver Network for Lung Tumor and Bronchial Premalignant Lesion Stratification from Histopathology. Am J Pathol. 2024 Jul; 194(7):1285-1293. PMID: 38588853.
Read at: PubMed - Published on 11/13/2023
Ma L, Sullivan TB, Rieger-Christ KM, Yambayev I, Zhao Q, Higgins SE, Yilmaz OH, Sultan L, Servais EL, Suzuki K, Burks EJ. Vascular invasion predicts the subgroup of lung adenocarcinomas =2.0 cm at risk of poor outcome treated by wedge resection compared to lobectomy. JTCVS Open. 2023 Dec; 16:938-947. PMID: 38204657.
Read at: PubMed - Published on 7/8/2023
Jamil ML, Perecman A, Sherman A, Sullivan T, Christ K, Hansma A, Burks E, Vanni AJ. Urinary microbiome differences between lichen sclerosus induced and non-lichen sclerosus induced urethral stricture disease. World J Urol. 2023 Sep; 41(9):2495-2501. PMID: 37421420.
Read at: PubMed - Published on 12/25/2022
Suaiti L, Sullivan TB, Rieger-Christ KM, Servais EL, Suzuki K, Burks EJ. Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma. Clin Lung Cancer. 2023 May; 24(3):e126-e133. PMID: 36631388.
Read at: PubMed
View 45 more publications: View full profile at BUMC